TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00423670

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: boceprevir (SCH 503034)
Description: 200 mg capsules taken as 800 mg orally three times daily (TID)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: boceprevir (SCH 503034)
Description: 200 mg capsules taken as 800 mg orally three times daily (TID)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: boceprevir (SCH 503034)
Description: 200 mg capsules taken as 800 mg orally three times daily (TID)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: boceprevir (SCH 503034)
Description: 200 mg capsules taken as 800 mg orally three times daily (TID)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: boceprevir (SCH 503034)
Description: 200 mg capsules taken as 800 mg orally three times daily (TID)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: boceprevir (SCH 503034)
Description: 200 mg capsules taken as 800 mg orally three times daily (TID)
Study: NCT02345642

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: VenaFlow Elite Standing
Study: NCT00423670

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: boceprevir (SCH 503034)
Description: 200 mg capsules taken as 800 mg orally three times daily (TID)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: peginterferon-alfa 2b (PegIntron)
Description: 1.5 μg/kg subcutaneously (SC) once weekly (QW)
Study: NCT03670082

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lu AF35700
Description: 20 mg Lu AF35700 single oral dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lu AF35700
Description: 20 mg Lu AF35700 single oral dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lu AF35700 iv
Description: 100 μg \[14C\]-Lu AF35700 (4.7 μCi/174 kBq) single intravenous micro-dose
Study: NCT00568789

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ramelteon, zolpidem and placebo
Description: Ramelteon 8 mg, tablets, orally, one night only during Period 1, 2 or 3~Zolpidem 10 mg, tablets, orally, one night only during Period 1, 2 or 3~Ramelteon/Zolpidem placebo-matching tablets, orally one night only during Period 1, 2 or 3
Study: NCT05165576

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Child-centered communication
Description: The child is asked for ideas, fears and concerns regarding the magnetic resonance imaging exam and responses are tailored to these individual needs

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Child-centered communication
Description: The child is asked for ideas, fears and concerns regarding the magnetic resonance imaging exam and responses are tailored to these individual needs
Study: NCT02008929

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: MG4101
Description: Ex vivo expanded allogeneic NK cell
Study: NCT02094586

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PXVX0200 Lot A
Description: Lot P700-1CA03

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PXVX0200 Lot B
Description: Lot P700-3CA03

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PXVX0200 Lot C
Description: Lot P700-6BA03

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT01224912

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Treatment
Description: The techniques used throughout the self-help manual are all effective in reducing insomnia: 1) Stimulus control: patients should only go to bed when sleepy, use the bed and bedroom for sleep (and sex) only, maintain a regular rising time, avoid daytime naps and get out of bed and go into another room when unable to fall asleep within 15-20 minutes (return only when sleepy). 2) progressive muscle relaxation. 3) sleep hygiene education (improving health and environmental factors that affect sleep). 3). Sleep restriction, whereby participants will stay only the time in bed that they sleep. 4) cognitive therapy to challenge and dispute incorrect and unhelpful thoughts about sleep (e.g. I must sleep at least 8 hours, otherwise I'll be a wreck tomorrow).
Study: NCT03756194

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Socially-assistive Pepper robot with a CARESSES cultural competence solution
Description: Week 1. On the first day, training will be provided to the participants enabling them to familiarise themselves with the robot's functionalities. The robot will be culturally aware i.e., it will be aware of the participants' cultural background prior to the testing commencing. As such, it will pre-load the appropriate CKB and apply this during its time with the participants. During the next two sessions, the robot will interact and provide culturally-competent assistance, however, it will not learn and adjust to the participants' individual cultural values and preferences.~Week 2. The participants will again utilize the robot for three days, but it now will learn from the responses it receives from them, consequently interacting in a culture-specific personalised way.

Intervention type: DEVICE
Group type: OTHER
Intervention: Socially-assistive control Pepper robot with an alternative CARESSES solution
Description: Week 1. On the first day, training will be provided to the participants enabling them to familiarise themselves with the robot's functionalities. During the next two sessions, the CARESSES control robot will not be culturally aware: it will pre-load a generic and more limited CKB that is not tailored for anyone's cultural profile. It will also not learn and adjust to the participants' values and preferences.~Week 2. Participants will again utilize the robot for three days, but the CARESSES control robot will now be configured to be able to learn and adapt to the individual's particular profile. This robot's learning will not include propagation: improving its cultural knowledge base in one area will not also automatically lead to knowledge improvements in other related areas. This robot will possess the same full suite of functions as the CARESSES robot although will be less likely to offer these in a culturally appropriate way.
Study: NCT01743651

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: arbaclofen
Description: 40 mg/day as 20 mg arbaclofen ER administered orally 2 times per day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: baclofen
Description: 80 mg/day as 20 mg baclofen administered orally 4 times per day

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: arbaclofen image matched placebo tablets administered orally 2 times/day or baclofen image matched placebo capsules administered orally 4 times/day
Study: NCT04377997

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Enoxaparin
Description: Given the established link between endothelial dysfunction and thrombosis in patients with cardiovascular disease9, 10 and the association between coagulopathy and adverse outcomes in patients with sepsis11, the association between increased coagulation activity, end-organ injury, and mortality risk may represent a modifiable risk factor among COVID-19 patients with critical illness. Therefore, we propose to conduct a randomized, open-label trial of therapeutic anticoagulation in COVID-19 patients with an elevated D-dimer to evaluate the efficacy. Most patients will receive low molecular weight heparin however, unfractionated heparin (UFH) will be administered for those with morbid obesity or moderate to severe renal dysfunction.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enoxaparin
Description: Given the established link between endothelial dysfunction and thrombosis in patients with cardiovascular disease9, 10 and the association between coagulopathy and adverse outcomes in patients with sepsis11, the association between increased coagulation activity, end-organ injury, and mortality risk may represent a modifiable risk factor among COVID-19 patients with critical illness. Therefore, we propose to conduct a randomized, open-label trial of therapeutic anticoagulation in COVID-19 patients with an elevated D-dimer to evaluate the efficacy. Most patients will receive low molecular weight heparin however, unfractionated heparin (UFH) will be administered for those with morbid obesity or moderate to severe renal dysfunction.
Study: NCT04651738

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: DNA methylation testing
Description: Methylation testing of host DNA, namely, BHLHE22, CELF4, HAND2, and ZNF177
Study: NCT00755755

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PGL4001 (ulipristal) and iron
Description: tablets

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: PGL4001 matching placebo and iron
Description: tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PGL4001 (ulipristal) and iron
Description: Tablets
Study: NCT01145144

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dehydroepiandrosterone crystalline fine powder
Study: NCT04701502

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Viusid
Description: Patients received daily doses of 30 ml of Viusid every 8 hours plus standard care for COVID-19. Viusid is administered orally.~Treatment duration: 21 days
Study: NCT00362687

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Truvada (TDF+FTC) alone
Description: tenofovir DF 300 mg and emtricitabine 200 mg in a fixed dose tablet formulation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FTC alone
Description: emtricitabine 200 mg

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: No HAART
Description: No HAART
Study: NCT02607163

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dexmedetomidine
Description: Immediately after the induction of anesthesia, patients in the dexmedetomidine group received dexmedetomidine continuous intravenous (IV) infusion of 0.4 mcg/kg/h until 24 hours after surgery.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: saline
Description: same infusion rate (received equal volume of normal saline), IV, The infusion of study drug is started after anesthesia induction and continued until 24 hours after surgery.
Study: NCT03151668

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Study: NCT00353119

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo comparator
Description: Patients received placebo subcutaneously twice weekly

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Etanercept
Description: Patients received etanercept 50 mg subcutaneously twice weekly

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Etanercept
Description: Patients received etanercept 50 mg subcutaneously twice weekly
Study: NCT00423670

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: peginterferon-alfa 2b (PegIntron)
Description: 1.5 μg/kg subcutaneously (SC) once weekly (QW)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: peginterferon-alfa 2b (PegIntron)
Description: 1.5 μg/kg subcutaneously (SC) once weekly (QW)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: peginterferon-alfa 2b (PegIntron)
Description: 1.5 μg/kg subcutaneously (SC) once weekly (QW)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: peginterferon-alfa 2b (PegIntron)
Description: 1.5 μg/kg subcutaneously (SC) once weekly (QW)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: peginterferon-alfa 2b (PegIntron)
Description: 1.5 μg/kg subcutaneously (SC) once weekly (QW)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: peginterferon-alfa 2b (PegIntron)
Description: 1.5 μg/kg subcutaneously (SC) once weekly (QW)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: peginterferon-alfa 2b (PegIntron)
Description: 1.5 μg/kg subcutaneously (SC) once weekly (QW)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ribavirin
Description: 200 mg capsules in doses of 800 to 1400 mg/day (based on weight) taken orally divided twice daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ribavirin
Description: 200 mg capsules in doses of 800 to 1400 mg/day (based on weight) taken orally divided twice daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ribavirin
Description: 200 mg capsules in doses of 800 to 1400 mg/day (based on weight) taken orally divided twice daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ribavirin
Description: 200 mg capsules in doses of 800 to 1400 mg/day (based on weight) taken orally divided twice daily
Study: NCT04701502

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Asbrip
Description: Patients received daily doses of 10 ml of Asbrip every 8 hours plus standard care for COVID-19. Asbrip is administered orally.~Treatment duration: 21 days

Intervention type: DRUG
Group type: OTHER
Intervention: Standard Care
Description: Standard care for COVID-19

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Standard Care
Description: Standard care for COVID-19
Study: NCT02531438

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omadacycline
Description: Injection for IV; Oral tablets

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Moxifloxacin
Description: IV solution; Oral tablets
Study: NCT02743663

Intervention type: PROCEDURE
Intervention: Bronchodilator response
Description: Bronchodilator (Salbutamol - dose dependent on participant prescription) to wheezing subjects. 15 minutes after bronchodilator, spirometry and FOT repeated.

Intervention type: PROCEDURE
Intervention: Allergy Skin Test
Description: Child will be tested for allergies to 17 different allergens, and positive (histamine) and negative (glycerin) controls, for a total of 19 allergens.

Intervention type: PROCEDURE
Intervention: Allergy Skin Test
Description: Child will be tested for allergies to 17 different allergens, and positive (histamine) and negative (glycerin) controls, for a total of 19 allergens.

Intervention type: PROCEDURE
Intervention: Multiple-Breath Washout
Description: Facemask in children 3-5 yrs, Wash-in phase: medical air inhaled during tidal breathing until steady state. Bias flow switched to 100% oxygen. Wash-out phase: patient breathes in 100% oxygen until nitrogen levels reach \~2%. Each test in duplicate and average is calculated.

Intervention type: PROCEDURE
Intervention: Multiple-Breath Washout
Description: Facemask in children 3-5 yrs, Wash-in phase: medical air inhaled during tidal breathing until steady state. Bias flow switched to 100% oxygen. Wash-out phase: patient breathes in 100% oxygen until nitrogen levels reach \~2%. Each test in duplicate and average is calculated.

Intervention type: PROCEDURE
Intervention: Forced Oscillation Technique
Description: Sterile mouthpiece attached to FOT device. Patient is tested seated with noseclips and mouthpiece. FOT device produces oscillations at different frequencies (from that flow into lungs. Device measures resistance and reactance in lungs.

Intervention type: PROCEDURE
Intervention: Forced Oscillation Technique
Description: Sterile mouthpiece attached to FOT device. Patient is tested seated with noseclips and mouthpiece. FOT device produces oscillations at different frequencies (from that flow into lungs. Device measures resistance and reactance in lungs.

Intervention type: PROCEDURE
Intervention: Spirometry
Description: Forced exhale manoeuvre completed by participant into flow meter, measuring forced exhale volumes and speed.

Intervention type: PROCEDURE
Intervention: Spirometry
Description: Forced exhale manoeuvre completed by participant into flow meter, measuring forced exhale volumes and speed.
Study: NCT00158652

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional radiotherapy 70 Gy in 7 weeks
Description: 2 gy per fraction, 1 fraction per day, 5 fractions per week

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: middle accelerated radiotherapy 70 Gy in 6 weeks
Description: 5 x 2gy/week until 40 Gy in 20 fractions and 4 weeks, then 2 fractions of 1.5Gy per day for 30 additional Gy in 2 weeks

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: very accelerated radiotherapy 64.8 Gy in 3.5 weeks
Description: 2 fractions of 1.8 Gy per day for 64.8 Gy in 3.5 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 5FU, Paraplatin
Description: 5FU 600mg/m²/D, Paraplatin 70mg/m²/D In arm 1: D1-4, 3 cycles during Rth (D1, D22, D43) In arm 2: D1-5, 2 cycles during Rth (D1, D29)
Study: NCT00423670

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ribavirin
Description: 200 mg capsules in doses of 800 to 1400 mg/day (based on weight) taken orally divided twice daily
Study: NCT00158652

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5FU, Paraplatin
Description: 5FU 600mg/m²/D, Paraplatin 70mg/m²/D In arm 1: D1-4, 3 cycles during Rth (D1, D22, D43) In arm 2: D1-5, 2 cycles during Rth (D1, D29)
Study: NCT01954121

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levetiracetam
Description: Immediate release film-coated tablets at strengths of 250 mg and 500 mg.~* Up-titration Period (Week 1 to Week 3): Levetiracetam (LEV) 250 mg twice daily (bid)~* Stabilization Period and Evaluation Period (Week 3 to Week 30): LEV 500 mg bid~* Down-titration Period (Week 30 up to Week 33)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carbamazepine
Description: Immediate release tablets at a strength of 200 mg.~* Up-titration Period (Week 1 to Week 3): Carbamazepine- Immediate Release (CBZ-IR) 200 mg once daily (qd)~* Stabilization Period and Evaluation Period (Week 3 to Week 30): CBZ-IR 200 mg bid~* Down-titration Period (Week 30 up to Week 33)
Study: NCT02120651

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Fibrin monomer
Description: Fibrin monomer by microscopic tympanoplasty, every 4 weeks up to 3 months is evaluated graft integrity by standard audiologic and tympanometric parameters.

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Hemostatic sponge
Description: Hemostatic sponge by microscopic tympanoplasty, every 4 weeks up to 3 months is evaluated graft integrity by standard audiologic and tympanometric parameters.
Study: NCT00362687

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: No HAART
Description: No HAART
Study: NCT03168035

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NC-4016
Description: Dose Escalation Group Starting Dose: 15 mg/m2 by vein on Day 1 of a 21 Day cycle.~Dose Expansion Group Starting Dose: Maximum tolerated dose from Dose Escalation Group.
Study: NCT01170715

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etanercept
Description: self-administered for 52 weeks
Study: NCT04262739

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NYH817G
Description: Subject will orally administer NYH817G (15 mg) during the cycles(21 days)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NYH100P
Description: Subject will orally administer NYH100P (100 mg) during the cycles(21 days)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NYH817G and NYH100P
Description: Subject will orally administer NYH817G (15 mg) and NYH100P (100 mg) during the cycles(21 days)
Study: NCT02212457

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Bexsero
Description: Two doses administered intramuscularly into the deltoid area at Months 0 and 2 in rMenB_0_2 Group.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Saline Placebo
Description: One dose administered intramusculary in the deltoid muscle at Month 1 in ABCWY_ 0_2 Group and rMenB_0_2 Group, Month 2 in ABCWY_0_6 Group and ABCWY_0_11 Group and Month 6 in ABCWY_0_1 Group.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Saline Placebo
Description: One dose administered intramusculary in the deltoid muscle at Month 1 in ABCWY_ 0_2 Group and rMenB_0_2 Group, Month 2 in ABCWY_0_6 Group and ABCWY_0_11 Group and Month 6 in ABCWY_0_1 Group.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Saline Placebo
Description: One dose administered intramusculary in the deltoid muscle at Month 1 in ABCWY_ 0_2 Group and rMenB_0_2 Group, Month 2 in ABCWY_0_6 Group and ABCWY_0_11 Group and Month 6 in ABCWY_0_1 Group.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Saline Placebo
Description: One dose administered intramusculary in the deltoid muscle at Month 1 in ABCWY_ 0_2 Group and rMenB_0_2 Group, Month 2 in ABCWY_0_6 Group and ABCWY_0_11 Group and Month 6 in ABCWY_0_1 Group.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Saline Placebo
Description: One dose administered intramusculary in the deltoid muscle at Month 1 in ABCWY_ 0_2 Group and rMenB_0_2 Group, Month 2 in ABCWY_0_6 Group and ABCWY_0_11 Group and Month 6 in ABCWY_0_1 Group.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Havrix
Description: Two doses administered in the deltoid muscle at Month 2 and 12 in ABCWY_0_1 Group, Month 1 and 12 in Group ABCWY_0_6 Group and ABCWY_0_2_6 Group , Month 0 and 6 in ABCWY_0_11 Group and Month 6 and 12 in ABCWY_ 0_2 Group and rMenB_0_2 Group.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Havrix
Description: Two doses administered in the deltoid muscle at Month 2 and 12 in ABCWY_0_1 Group, Month 1 and 12 in Group ABCWY_0_6 Group and ABCWY_0_2_6 Group , Month 0 and 6 in ABCWY_0_11 Group and Month 6 and 12 in ABCWY_ 0_2 Group and rMenB_0_2 Group.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Havrix
Description: Two doses administered in the deltoid muscle at Month 2 and 12 in ABCWY_0_1 Group, Month 1 and 12 in Group ABCWY_0_6 Group and ABCWY_0_2_6 Group , Month 0 and 6 in ABCWY_0_11 Group and Month 6 and 12 in ABCWY_ 0_2 Group and rMenB_0_2 Group.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Havrix
Description: Two doses administered in the deltoid muscle at Month 2 and 12 in ABCWY_0_1 Group, Month 1 and 12 in Group ABCWY_0_6 Group and ABCWY_0_2_6 Group , Month 0 and 6 in ABCWY_0_11 Group and Month 6 and 12 in ABCWY_ 0_2 Group and rMenB_0_2 Group.
Study: NCT00423670

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ribavirin
Description: 200 mg capsules in doses of 800 to 1400 mg/day (based on weight) taken orally divided twice daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ribavirin
Description: 200 mg capsules in doses of 800 to 1400 mg/day (based on weight) taken orally divided twice daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ribavirin (low-dose)
Description: 200 mg capsules in doses of 400 to 1000 mg/day (based on weight) taken orally divided twice daily
Study: NCT02028338

Intervention type: COMBINATION_PRODUCT
Group type: PLACEBO_COMPARATOR
Intervention: placebo ring
Description: intravaginal ring silicone elastomer intravaginal ring containing no drug product
Study: NCT01729260

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mebendazole
Description: The mebendazole will be given by mouth three times every day on a 28 day cycle. it's in the form of 500 mg chewable tablets, to be taken with meals.
Study: NCT03190369

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hylan G-F 20 (GZ402662/SAR402662)
Description: Pharmaceutical form: Solution for injection~Route of administration: Intra articular